Anxiety and Depression Treatment Market By Product (Antidepressant Drugs, SSRIs (Selective Serotonin Reuptake Inhibitor), SNRIs (Serotonin-Norepinephrine Reuptake Drug), Benzodiazepine, Devices and Therapy), By Indication (MDD (Major Depressive Disorder), OCD (Obsessive-Compulsive Disorder), Phobia), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

Anxiety and depression disorders are a major cause of mental illness. Depression is more than just a feeling down or having a bad day.  When a sad mood lasts for a long time & interferes with normal, everyday functioning, you may be depressed. Feeling sad, irritated, anxious, experiencing headaches, pains, lack of sleep are the major symptoms of anxiety and depression. The factors that increase a persons chances of becoming depressed are: Going through a major life change, even if it was already planned, having severe disease like cancer, chronic pain or stroke. Experiencing traumatic or stressful events, such as physical or sexual abuse, death of loved one, or financial problems. Using alcohol or drugs

Globally, anxiety and depression has become the most increasing psychiatric disorder. Depression comorbid with anxiety has been associated with poorer health outcomes, including more severe symptoms & higher levels of suicidal ideation. Covid-19 has disrupted mental health services in most countries, WHO survey. Pandemic has increase the demand for mental health services which includes treatment and thus expected to increase in growth of target market. The global Anxiety and Depression Treatment market size accounted for US$ 10.89 billion in 2020 and is estimated to be US$ 13.85 billion by 2030 and is anticipated to register a CAGR of 2.7%.

                                   Rise in mental illness and rate of newly medications

Rise in mental health illness of an individual is one of the leading factors for the global anxiety and depression treatment market growth. Moreover, increasing urban population is one of the driving factors for the global anxiety and depression treatment market. Urban culture affects the person’s living lifestyle. Living lonely causes the mental illness which requires development of treatment. The pandemic has driven the life of people much more harder and led to increase in anxiety and depression. However, the growth in research and development to overcome the mental illness in urban areas boosts the demand for target market.

                                                           Technological advancement

Technology has made a big impact on the treatment of chronic illnesses, such as major depression, because technology offers self-management strategies & significantly improves adherence to medications with reminders & messages of support. Digital care options through Teletherapy & all new apps have seen explosive growth during the pandemic.

Restrains:

Digital Technology helps depression sufferers who can’t take medicines. Increase in use of new Teletherapy and new apps has somewhat restrain the growth of target market.

Source: Prophecy Market Insights

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

The global anxiety and depression treatment market is segmented based on product, indication, distribution channel, and region.

On the basis of product, the global anxiety and depression treatment market is segmented into Antidepressant drugs, SSRIs (Selective Serotonin Reuptake Inhibitor), SNRIs (Serotonin-Norepinephrine Reuptake Drug), Benzodiazepine, Devices and Therapy. On the basis of indication, the target market is segmented into MDD (Major Depressive Disorder), OCD (Obsessive-Compulsive Disorder), Phobia. On the basis of distribution channel the global anxiety and depression treatment market is classified into hospital pharmacy, retail pharmacy, and online pharmacy and others.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

On region the global anxiety and depression treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia-pacific market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as India and China, and technological advancements. Moreover, rising presence of industrial corridor is anticipated to increase demand for anxiety and depression treatment in the region.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the global anxiety and depression treatment report based on product, indication, distribution channel and region:

Global Anxiety and Depression Market, By Product:

• Antidepressant Drugs
• SSRIs (Selective Serotonin Reuptake Inhibitor)
• SNRIs (Serotonin Norepinephrine Reuptake Drug)
• Benzodiazepine
• Devices
• Therapy

Global Anxiety and Depression Market, By Indication:

• MDD (Major Depressive Disorder)
• OCD (Obsessive-Compulsive Disorder)
• Phobia

Global Anxiety and Depression Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Anxiety and Depression Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating the global anxiety and depression treatment market includes Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., AstraZeneca, Bristol-Myers Sqibb, Lundbeck A/S, GlaxoSmithKline plc., Novartis AG, Sanofi, Cipla Ltd., Glenmark Life Sciences Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Intas Pharmaceutical Industries Ltd., Mylan N.V., Sumitomo Dainippon Pharma Co. Ltd., and Others. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market. For instance, in 2018, Novartis Use Self-Tracking App to determine Prevalence of Anxiety, Depression in Migraine. Digital health company & drug maker Novartis have announced joint research pointing to an increase in anxiety & depression with higher migraine frequency among tens of thousands of patients with migraine in the United States.

• Novartis AG*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Pfizer Inc.,
• Eli Lilly and Company
• Johnson & Johnson
• Merck & Co. Inc.,
• AstraZeneca
• Bristol Myers Sqibb
• Lundbeck A/S
• GlaxoSmithKline plc.,
• Novartis AG
• Sanofi
• Cipla Ltd.,
• Glenmark Lifesciences Limited
• Lupin Limited
• Sun Pharmaceutical Industries Ltd.,
• Intas Pharmaceutical Industries Ltd.,
• Mylan N.V.,
• Sumitomo Dainippon Pharma Co. Ltd.

 “*” marked represents similar segmentation in other categories in the respective section